Bristol buys Cafcit
Executive SummaryBristol-Myers Squibb subsidiary Mead Johnson purchases Cafcit (caffeine citrate) from OPR Development. Cafcit is only drug approved for short-term (10-12 days) treatment of apnea of prematurity in infants between 28 and 33 weeks gestational age, Bristol says...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.